In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bellicum Pharmaceuticals Inc.

www.bellicum.com

Latest From Bellicum Pharmaceuticals Inc.

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.

Financing Strategy

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.

ImmunoOncology Research and Development Strategies

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More

Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights include new treatments for beta-thalassemia, such as Acceleron's and Celgene's luspatercept.

Clinical Trials Cancer

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bellicum Pharmaceuticals Inc.
  • Senior Management
  • Rick Fair, Pres. & CEO
    Atabak Mokari, CFO
    Gregory Naeve, PhD, CBO
    Aaron Foster, PhD, SVP, Head, Research
  • Contact Info
  • Bellicum Pharmaceuticals Inc.
    Phone: (832) 384-1100
    2130 West Holcombe Blvd.
    Ste. 800
    Houston, TX 77030
    USA
UsernamePublicRestriction

Register